The association of p16INK4A and fragile histidine triad gene expression and cervical lesions

Journal of Lower Genital Tract Disease

Volumn 11, Issue 3, 2007, Pages 151-157

  Longatto Filho, Adhemar ^a,b   Etlinger, Daniela ^a   Pereira, Sônia Maria Miranda ^a   Kanamura, Cristina Takami ^a   Di Loreto, Celso ^a   Santos, Gilda Da Cunha ^c,d   Makabe, Sérgio ^e   Marques, José A ^e   Santoro, Carmen L F ^e   Das Dores, Gerson Botacini ^f   Castelo, Adauto ^g  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF TORONTO   (Canada)

^d CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

^e Hospital Perola Byington   (Brazil)

^f Digene Brasil   (Brazil)

^g FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cervical cancer; FHIT; HPV; Liquid based cytology; P16

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN P16; PROTEIN P16INK4A;

ARTICLE; BRAZIL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ACID ANHYDRIDE HYDROLASES; ALPHAPAPILLOMAVIRUS; AREA UNDER CURVE; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PAPILLOMAVIRUS INFECTIONS; ROC CURVE; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; UTERINE CERVICITIS;

EID: 34347340664     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31802efb9e     Document Type: Article

References (29)

1. Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, et al. Cervical cancer control, priorities and new directions. Int J Cancer 2004;108:329-33.
2. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
3. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
5. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uterine. Int J Cancer 2001;92:276-84.
6. Santos M, Montagut C, Mellado B, Garcia A, Ramon y Cajal S, Cardesa A, et al. Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol 2004;23:206-14.
7. Lu DW, El-Mofty SK, Wang HL. Expression of p16 and p53 in squamous cell carcinomas of the anorectal region harbouring human papillomavirus DNA. Mod Pathol 2003;16:692-9.
8. Ferreux E, Lont AP, Horenblas S, Gallee MP, Raaphorst FM, von Knebel Doeberitz M, et al. Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol 2003;201:109-18.
9. Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS, et al. P16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol 2004;190:668-73.
10. Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, et al. The presence of high-risk HPV combined with specific p53 and p16INK4A expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-43.
11. Alfsen GC, Reed W, Sandstad B, Kristensen GB, Abeler VM. The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinoma of the cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma. Cancer 2003;98:1880-9.
12. Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004;28:160-7.
13. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999;17:1618-24.
14. Butler D, Collins C, Mabruk M, Barry Walsh C, Leader MB, Kay EW. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. J Pathol 2000;192:502-10.
15. Butler D, Collins C, Mabruk M, Leader MB, Kay EW. Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer. Gynecol Oncol 2002;86:144-9.
16. Hidalgo A, Baudis M, Petersen I, Arreola H, Pina P, Vazquez-Ortiz G, et al. Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer 2005;5:77. Available at: http://www.biomedicalcentral.com/1471-2407/5/77.
17. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System Terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
18. Tavassoli FA, Deville P. Tumours of the breast and female genital organs. World Health Organization Classification of Tumours 2003. Lyon, France: IARC Press, WHO.
19. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
20. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-42.
21. Wang SS, Trunk M, Schiffman M, Herrero R, Sherman ME, Burk RD, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:1355-60.
22. Longatto Filho A, Utagawa ML, Shirata NK, Pereira SM, Namiyama GM, Kanamura CT, et al. Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal Pap smears positive for oncogenic human papillomavirus. Int J Gynecol Pathol 2005;24:118-24.
23. Franco EL, Ferenczy A. Is HPV testing with cytological triage a more logical approach in cervical cancer screening? Lancet Oncol 2006;7:527-9.
24. Holschneider CH, Baldwin RL, Tumber K, Aoyama C, Karlan BY. The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer. Clin Cancer Res 2005;11:5756-63.
25. Lea JS, Ashfaq R, Muneer S, Burbee DG, Miller DS, Minna JD, et al. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. J Soc Gynecol Investig 2004;11:329-37.
26. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, et al. Loss of FHIT expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 2000;6:3505-10.
27. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, et al. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 1999;59:5270-4.
28. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006;66:4049-54.
29. Kinney WK, Fetterman B, Pawlick G. Lessons From Practice: The Two Hundred Thousand Pap and HPV Cotests for General Population Screening. Paris, France: Eurogin, 2006. SS09-03.